Orforglipron

Oral non-peptide small-molecule GLP-1 receptor agonist (Eli Lilly); investigational daily oral agent for obesity and type 2 diabetes.

Quick Facts

Property	Value
Also Known As	LY3502970
Category	Non-Peptide GLP-1 Receptor Agonist (Small Molecule)
Sequence	N/A — Orforglipron is NOT a peptide. It is a small-molecule organic compound.
Molecular Weight	~632 Da
Molecular Formula	C34H36F3N3O3S (approximate)
PubChem CID	163452725
Administration	Oral, once daily
Typical Dose Range	12-45 mg once daily (Phase 2 dose range)
Half-Life	~29 hours
Storage	Room temperature (investigational)
FDA Status	Investigational — Phase 3 (ATTAIN program for obesity and T2D)
WADA Status	Not listed (investigational)

CRITICAL CLASSIFICATION NOTE: Orforglipron is explicitly NOT a peptide. It is a small-molecule, non-peptide GLP-1 receptor agonist. It is included in this vault because:

It activates the same GLP-1 receptor (GLP1R, UniProt P43220) targeted by peptide-based GLP-1 RAs (semaglutide, exenatide, dulaglutide, liraglutide)

Practitioners using injectable GLP-1 peptides MUST understand the oral non-peptide alternatives their patients will ask about

If orforglipron achieves Phase 3 success, it could fundamentally shift the injectable-vs-oral treatment paradigm for obesity and T2D

This parallels the vault's inclusion of other non-peptide compounds like MK-677 (non-peptide GH secretagogue), Relugolix (non-peptide GnRH antagonist), and Elagolix (non-peptide GnRH antagonist) that act on peptide-relevant receptor systems

Mechanism of Action

Orforglipron is a small-molecule agonist of the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Unlike all currently approved GLP-1 RAs, which are either peptide analogs (semaglutide, liraglutide, exenatide, dulaglutide) or modified peptides requiring injection, orforglipron is a fully synthetic non-peptide compound that can be absorbed orally without requiring the permeation enhancer (SNAC) needed by oral semaglutide (Rybelsus).

Orforglipron binds to the GLP-1R at a site partially overlapping with the orthosteric peptide-binding site but with a distinct binding mode that explains its unique pharmacological properties. Upon binding, orforglipron activates the same downstream signaling cascades as peptide GLP-1 RAs: Gs-protein coupling leading to cAMP production, PKA and Epac2 activation, and beta-arrestin recruitment. This produces the canonical GLP-1R effects:

Glucose-dependent insulin secretion from pancreatic beta cells
Suppression of glucagon secretion from alpha cells (glucose-dependent)
Delayed gastric emptying reducing postprandial glucose excursions
Central appetite suppression via hypothalamic and brainstem GLP-1R activation
Potential cardioprotection through vascular and cardiac GLP-1R signaling

The key pharmacological advantages of the small-molecule approach include:

Oral bioavailability — No injection required; no SNAC/permeation enhancer needed (unlike oral semaglutide)
Chemical stability — Not susceptible to peptidase degradation; stable at room temperature
Manufacturing simplicity — Small-molecule synthesis is scalable and potentially less expensive than peptide manufacturing
29-hour half-life — Supports once-daily dosing with stable plasma concentrations

Key Research Areas

Obesity/Weight Loss — Phase 2 NEJM trial showed 9.4-14.7% body weight loss at 36 weeks; comparable to injectable GLP-1 RAs (PMID: 37351564)
Type 2 Diabetes — Phase 2 Lancet trial demonstrated HbA1c reductions up to -2.10% and weight loss up to -10.1 kg; superior to dulaglutide 1.5 mg (PMID: 37369232)
Oral GLP-1 RA Development — First non-peptide oral GLP-1 RA to demonstrate clinical efficacy comparable to injectable agents
Phase 3 Program (ATTAIN) — Multiple Phase 3 trials underway for obesity and T2D; results expected 2025-2026

Evidence Level Summary

Evidence Type	Count	Notes
Human RCTs	4+	Phase 1a/1b, Phase 2 (obesity), Phase 2 (T2D), Phase 3 ongoing
Human observational	0	Investigational — no real-world data
Animal in vivo	5+	Preclinical pharmacology and toxicology
In vitro	5+	GLP-1R binding, signaling characterization
Systematic reviews	2+	Meta-analyses of Phase 2 data

Clinical Applications

Weight Management — Investigational; Phase 2 showed ~15% weight loss at highest dose
Type 2 Diabetes — Investigational; superior glycemic control vs. dulaglutide
Metabolic Syndrome — Broad cardiometabolic improvements observed

Protocols Using This Peptide

No current vault protocols include orforglipron as it remains investigational and is a non-peptide compound. However, practitioners following the Weight Loss Protocol or Metabolic Reset Protocol should understand orforglipron as a potential future oral alternative to injectable GLP-1 RAs.

Ageless Peps Products

Orforglipron is an investigational drug (Eli Lilly) and is NOT sold by Ageless Peps. As a non-peptide compound, it would not fall within Ageless Peps' peptide product category even if approved.

Dosing Reference

Clinical Trial Dosing (Investigational)

Route	Dose Range	Frequency	Duration	Source
Oral (Obesity)	12, 24, 36, 45 mg	Once daily	36 weeks (Phase 2)	PMID 37351564
Oral (T2D)	3, 12, 24, 36, 45 mg	Once daily	26 weeks (Phase 2)	PMID 37369232

Dose Escalation

Phase 2 trials used dose escalation over the first 12-29 days to mitigate GI adverse effects. The optimal dose for weight loss appears to be 36-45 mg daily. The optimal dose for T2D appears to be 12 mg or higher.

Cycling

Not applicable (chronic therapy in clinical trials).

Contraindications & Safety

Contraindications (from trials): History of MTC, MEN2 (precautionary GLP-1 RA class label)
Common side effects: Nausea (dose-dependent, most common), vomiting, diarrhea, constipation, decreased appetite — GI event rates (44-70%) similar to injectable GLP-1 RAs
Drug interactions: Delayed gastric emptying may affect oral medication absorption (class effect)
Pregnancy/nursing: Not studied; expected contraindication
Special populations: Limited data; Phase 1 PK studies in hepatic/renal impairment ongoing
Notable: No cases of pancreatitis or medullary thyroid carcinoma in Phase 2 trials

Why Practitioners Must Understand Orforglipron

The emergence of orforglipron represents a potential paradigm shift in metabolic peptide therapy:

Patient demand for oral alternatives — Many patients prefer pills over injections; orforglipron could capture significant market share from injectable GLP-1 peptides
Accessibility — Oral administration removes barriers of injection training, needle disposal, and cold-chain storage
Pricing competition — Small-molecule manufacturing is potentially cheaper than peptide production, which could impact pricing across the GLP-1 RA category
Differentiation opportunity for injectable peptides — If oral non-peptide GLP-1 RAs achieve comparable efficacy, injectable peptide therapists must articulate the unique value of their modality (e.g., multi-peptide stacking, dose flexibility, combination protocols)

Competitive Landscape

Agent	Type	Route	Key Differentiator
Semaglutide	Peptide GLP-1 RA	SubQ or Oral (SNAC)	Gold standard; 15-17% weight loss
Tirzepatide	Peptide GIP/GLP-1 RA	SubQ	20%+ weight loss; dual mechanism
Exenatide	Peptide GLP-1 RA	SubQ	First-in-class; moderate efficacy
Dulaglutide	Fusion protein GLP-1 RA	SubQ	CV benefit (REWIND); user-friendly pen
Orforglipron	Non-peptide GLP-1 RA	Oral (no SNAC)	First oral non-peptide; ~15% weight loss; daily pill

Related Research

Identifier	Title	Year	Study Type
PMID 37351564	Daily oral GLP-1 receptor agonist orforglipron for adults with obesity	2023	RCT (Phase 2)
PMID 37369232	Efficacy and safety of oral orforglipron in patients with type 2 diabetes	2023	RCT (Phase 2)
DOI-10-1056-NEJMoa2511774 – ATTAIN-1 Orforglipron Obesity	Orforglipron for Obesity (ATTAIN-1, Phase 3, n=3,127)	2025	RCT (Phase 3)

ATTAIN-1 (Phase 3) — November 2025 NEJM

Wharton S et al., N Engl J Med 2025;393(19):1889-1901. doi: 10.1056/NEJMoa2511774.

Dose	Mean weight loss at 72 weeks
Orforglipron 36 mg daily	-14.6%
Orforglipron 24 mg daily	-12.8%
Orforglipron 12 mg daily	-8.2%
Placebo	-2.0%

Clinical significance: First oral non-peptide GLP-1 agonist to achieve Phase 3 efficacy within the range of injectable semaglutide 2.4 mg (STEP 1: -14.9%). No food/water/timing restrictions (unlike oral peptide semaglutide / Rybelsus). Manufacturing scalability via chemical synthesis may substantially expand access. FDA NDA filed; approval status pending — verify FDA.gov at time of reference.

References

PMID 37351564 — Phase 2 obesity trial (NEJM 2023)
PMID 37369232 — Phase 2 T2D dose-response trial (Lancet 2023)
DOI 10.1056/NEJMoa2511774 — ATTAIN-1 Phase 3 obesity trial (NEJM 2025)

#metabolic #investigational #not-sold #oral